Completed PHASE1 INTERVENTIONAL 3-arm NCT02191462

A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects (14NBHC)

A Randomized, Double-blind, Cross-over Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects

Sponsor: ChromaDex, Inc.

Interventions Niagen 1000mg Niagen 100mg Niagen 300mg

Updated 6 times since 2017 Last updated: Sep 8, 2014 Started: Jul 31, 2014 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Pharmacokinetics, this trial is completed. The trial is conducted by ChromaDex, Inc. and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Sep 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ChromaDex, Inc.
KGK Science Inc.

Data source: KGK Science Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, Canada